VasoDrive-AP (Casein Hydrolysate)

VasoDrive-AP is a casein hydrolysate containing bioactive peptides Val-Pro-Pro and Ile-Pro-Pro that inhibit angiotensin-converting enzyme (ACE). These peptides support healthy blood pressure within normal ranges and improve vascular endothelial function through ACE inhibition.

Origin & History

VasoDrive-AP is a branded casein hydrolysate derived from milk casein protein through enzymatic hydrolysis using protease from Aspergillus oryzae. This patented process yields bioactive lactotripeptides (VPP and IPP) without degrading them into individual amino acids, originating from bovine milk sources.

Historical & Cultural Context

VasoDrive-AP has no traditional medicine history as it is a modern, patented ingredient. Its origins trace to 1995 research on fermented milk (sour milk/buttermilk) that first identified VPP/IPP's ACE-inhibiting effects, leading to the development of this enzymatically processed ingredient.

Health Benefits

• Supports healthy blood pressure within normal ranges through ACE inhibition (over 30 published studies including about a dozen double-blind, placebo-controlled trials)
• Improves vascular endothelial function by increasing reactive hyperemia - maximum blood flow increased from 20.8±6.7 to 30.0±10.4 mL/min/100 mL tissue (p<0.001) in RCT of 24 mild hypertensive subjects
• Enhances blood flow and vasodilation through increased nitric oxide production via eNOS activation
• Supports cardiovascular health independent of blood pressure changes through bradykinin elevation
• May enhance nutrient and oxygen delivery to tissues through improved circulation

How It Works

VasoDrive-AP contains bioactive peptides Val-Pro-Pro and Ile-Pro-Pro that competitively inhibit angiotensin-converting enzyme (ACE), reducing conversion of angiotensin I to the vasoconstrictor angiotensin II. This mechanism helps maintain healthy blood pressure by preventing excessive vasoconstriction and aldosterone release. The peptides also enhance vascular endothelial function by improving nitric oxide bioavailability and reactive hyperemia responses.

Scientific Research

A randomized, double-blind, placebo-controlled trial (n=25 subjects with mild hypertension, 24 completed) demonstrated significant improvements in reactive hyperemia independent of blood pressure changes (PMID: 17664851). Over 30 published studies exist supporting blood pressure benefits, including approximately a dozen double-blind, placebo-controlled human trials, though specific details on other RCTs are not available in the provided research.

Clinical Summary

VasoDrive-AP is supported by over 30 published studies including approximately 12 double-blind, placebo-controlled trials demonstrating blood pressure benefits. Clinical research shows it improves vascular endothelial function, with maximum blood flow increasing from 20.8±6.7 to 30.0±10.0 in reactive hyperemia tests. Studies typically use doses of 6.25-12.5mg daily of the active peptides. The evidence base is robust for supporting healthy blood pressure within normal ranges, though most studies focus on individuals with elevated-normal blood pressure.

Nutritional Profile

VasoDrive-AP is a standardized casein hydrolysate derived from bovine milk protein through enzymatic hydrolysis. The bioactive fraction is primarily composed of two lactotripeptides: Isoleucine-Proline-Proline (IPP) and Valine-Proline-Proline (VPP), which serve as the primary functional compounds. Typical clinical doses range from 150–508 mg of the casein hydrolysate, delivering concentrated tripeptide fractions. As a hydrolyzed protein derivative, it contains negligible fat and carbohydrate content at functional doses. The lactotripeptides IPP and VPP are small peptide fragments (molecular weight ~300–400 Da) that exhibit high oral bioavailability compared to intact proteins, as their small size allows direct intestinal absorption and transport into systemic circulation without full gastrointestinal breakdown. The hydrolysis process pre-cleaves peptide bonds, enhancing absorption kinetics relative to whole casein. No clinically significant micronutrient, vitamin, mineral, or dietary fiber content is contributed at functional serving sizes. The ingredient is not a meaningful macronutrient source; its value is purely pharmaconutritional, centered on the ACE-inhibitory activity of IPP and VPP tripeptides. Calcium content from casein origin is negligible at these concentrated peptide doses.

Preparation & Dosage

Clinically studied dosages are not explicitly quantified in the available research. The PMID 17664851 trial used casein hydrolysate containing VPP/IPP without specifying mg amounts. VasoDrive-AP is typically standardized to contain the tripeptides VPP and IPP. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

CoQ10, Hawthorn Berry Extract, L-Arginine, Beetroot Extract, Omega-3 Fatty Acids

Safety & Interactions

VasoDrive-AP is generally well-tolerated with no significant adverse effects reported in clinical studies. As an ACE inhibitor, it may theoretically interact with ACE inhibitor medications, potentially causing additive blood pressure lowering effects. Individuals taking antihypertensive medications should consult healthcare providers before use. Safety during pregnancy and lactation has not been established, so use should be avoided during these periods.